Statements (50)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
antiemetic |
| gptkbp:approvedBy |
1990
|
| gptkbp:ATCCode |
gptkb:A04AA01
|
| gptkbp:brand |
gptkb:Zofran
gptkb:Emeset gptkb:Ondemet |
| gptkbp:CASNumber |
99614-02-5
|
| gptkbp:chemicalClass |
carbazole derivative
|
| gptkbp:contraindication |
hypersensitivity to ondansetron
|
| gptkbp:discoveredBy |
GlaxoSmithKline
|
| gptkbp:eliminationHalfLife |
3-6 hours
|
| gptkbp:excretion |
urine
feces |
| gptkbp:form |
gptkb:tablet
oral solution solution for injection oral disintegrating tablet |
| gptkbp:genericAvailable |
yes
|
| gptkbp:hasMolecularFormula |
C18H19N3O
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ondansetron
|
| gptkbp:IUPACName |
9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-2,3,4,9-tetrahydro-1H-carbazol-4-one
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
serotonin 5-HT3 receptor antagonist
|
| gptkbp:metabolism |
liver
|
| gptkbp:patentExpired |
2006 (US)
|
| gptkbp:pregnancyCategory |
B (US)
B1 (Australia) |
| gptkbp:proteinBinding |
70-76%
|
| gptkbp:PubChem_CID |
4595
DB00904 |
| gptkbp:routeOfAdministration |
oral
intramuscular intravenous sublingual |
| gptkbp:sideEffect |
constipation
dizziness fatigue headache QT prolongation |
| gptkbp:synonym |
gptkb:GR_38032F
|
| gptkbp:UNII |
4QWG6N8QKH
|
| gptkbp:usedFor |
chemotherapy-induced nausea and vomiting
postoperative nausea and vomiting radiotherapy-induced nausea and vomiting prevention of nausea and vomiting treatment of nausea and vomiting |
| gptkbp:WHOModelListOfEssentialMedicines |
included
|
| gptkbp:bfsParent |
gptkb:Antiemetics
|
| gptkbp:bfsLayer |
6
|